Cellebrite DI (NASDAQ:CLBT) Insider Thomas Hogan Sells 25,299 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) insider Thomas Hogan sold 25,299 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares in the company, valued at approximately $8,639,661.21. The trade was a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Cellebrite DI Stock Up 5.8%

Shares of CLBT stock opened at $12.29 on Friday. Cellebrite DI Ltd. has a 12-month low of $9.58 and a 12-month high of $19.98. The company has a market capitalization of $3.07 billion, a P/E ratio of 55.87, a P/E/G ratio of 1.78 and a beta of 1.18. The firm has a 50-day moving average price of $14.18 and a 200 day moving average price of $13.79.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CLBT. Lake Street Capital cut their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. decreased their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. DA Davidson dropped their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, August 13th. Finally, Needham & Company LLC reduced their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.70.

Hedge Funds Weigh In On Cellebrite DI

A number of large investors have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC acquired a new position in Cellebrite DI during the 3rd quarter worth $40,000. CWM LLC lifted its holdings in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares in the last quarter. Elevation Wealth Partners LLC acquired a new position in Cellebrite DI during the 2nd quarter worth $44,000. Finally, Vestcor Inc bought a new position in Cellebrite DI in the 3rd quarter valued at $70,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.